Empagliflozin to prevent worsening of left ventricular volumes and systolic function after myocardial infarction

1 September 2024 (16:51 - 17:03)

Organised by:

Video

Sign in for access options

Slides

About the speaker

Doctor Jaclyn Carberry

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)

4 More presentations in this session

Presentation thumbnail

Strain sUrveillance during Chemotherapy for improving Cardiovascular Outcomes: Results of a Randomized Trial of Cardioprotection for Reduced Myocardial Strain (SUCCOUR-MRI)

Professor T. Marwick (Melbourne, AU)

Presentation thumbnail

Catheter Ablation versus Medical Rate Control in Atrial Fibrillation with Left Ventricular Systolic Dysfunction and Myocardial Fibrosis - The CAMERA-MRI II Randomized Trial

Associate Professor S. Prabhu (Melbourne, AU)

Presentation thumbnail

Sacubitril/valsartan compared to valsartan in regressing myocardial fibrosis in stage B heart failure: the REVERSE-LVH Trial

Doctor C. Chin (Singapore, SG)

Presentation thumbnail

Sacubitril/valsartan in primary prevention of cancer-therapy related cardiac dysfunction in breast cancer patients.

Doctor Y. Hsu (Tainan, TW)

Access the full session

Session thumbnail

Smaller trials: cardiac function and remodelling

The Event

Event poster

ESC Congress 2024

1 September 2024 16:51 CET

You may be interested in

Congress Session

Smaller trials: cardiac function and remodelling

Congress Presentation

The effect of empagliflozin on right ventricular function in heart failure patients with reduced ejection fraction: analysis from the randomized empire hf clinical trial

Congress Presentation

Cardiorenal effects and safety of initiation of empagliflozin after acute myocardial infarction

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources